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Nucleotide-binding and oligomerization domain NOD-like receptors (NLRs) are highly con-
served cytosolic pattern recognition receptors that perform critical functions in surveying
the intracellular environment for the presence of infection, noxious substances, and meta-
bolic perturbations. Sensing of these danger signals by NLRs leads to their oligomerization
into large macromolecular scaffolds and the rapid deployment of effector signaling cas-
cades to restore homeostasis. While some NLRs operate by recruiting and activating
inflammatory caspases into inflammasomes, others trigger inflammation via alternative
routes including the nuclear factor-κB, mitogen-activated protein kinase, and regulatory
factor pathways. The critical role of NLRs in development and physiology is demonstrated
by their clear implications in human diseases. Mutations in the genes encoding NLRP3
or NLRP12 lead to hereditary periodic fever syndromes, while mutations in CARD15 that
encodes NOD2 are linked to Crohn’s disease or Blau’s syndrome. Genome-wide associa-
tion studies (GWASs) have identified a number of risk alleles encompassing NLR genes in a
host of diseases including allergic rhinitis, multiple sclerosis, inflammatory bowel disease,
asthma, multi-bacillary leprosy, vitiligo, early-onset menopause, and bone density loss in
elderly women. Animal models have allowed the characterization of underlying effector
mechanisms in a number of cases. In this review, we highlight the functions of NLRs in
health and disease and discuss how the characterization of their molecular mechanisms
provides new insights into therapeutic strategies for the management of inflammatory
pathologies.
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INTRODUCTION
The mammalian immune system encompasses an ancient
genome-encoded innate immune system and a more recently
acquired adaptive immune system capable of combating
pathogens with exquisite specificity and long-term memory. The
innate immune system remains a pivotal player in controlling
host resistance. This system is equipped with an arsenal of pat-
tern recognition receptors (PRRs) that translate microbial and
danger sensing into immediate host defenses as well as provides
signals to prime the adaptive immune response for long-lasting
protection (1, 2). Nucleotide-binding and oligomerization domain
(NOD)-like receptors (NLRs) are a group of evolutionarily con-
served intracellular PRRs that play a vital role in innate immunity
and host physiology, as reflected by their prevalence among liv-
ing organisms of both the plant and animal kingdoms (3–9).
In humans there are 22 known NLRs, and the association of
mutations and single nucleotide polymorphisms (SNPs) in their
genes with human diseases reflect their vital role in host defense.
The function of NLRs is not restricted to immunity, as they also
play important roles in reproduction and embryonic development
(10–12).
The characteristic feature of NLRs is a central NOD (or
NACHT) domain, required for oligomerization, an N-terminal
homotypic protein–protein interaction domain and a C-terminal
series of leucine-rich repeats (LRRs) involved in agonist sensing or
ligand binding. Mammalian NLRs are sub-divided into four sub-
families based on the variation in their N-terminal domain: NLRA
or Class II transactivator (CIITA) contains an acid transactivation
domain, NLRBs or neuronal apoptosis inhibitor proteins (NAIPs)
possess a baculovirus inhibitor of apoptosis protein repeat (BIR),
NLRCs have a caspase-recruitment domain (CARD), and NLRPs
a pyrin domain (PYD). NLRX1 contains a CARD-related X effec-
tor domain (Figure 1). Upon ligand binding, the auto-inhibitory
LRR undergoes a conformational change, which exposes the N-
terminal domain allowing interaction with downstream signaling
adaptors or effectors and formation of an oligomeric complex (13,
14). NLR platforms that recruit and activate the inflammatory
protease caspase-1 are referred to as inflammasomes. Caspase-1
is required for the processing and maturation of inflammatory
cytokines IL-1β and IL-18 and the induction of an inflammatory
form of cell death termed pyroptosis (15, 16). Among the NLRs,
NLRP1, NLRP3, NLRP6, NLRP7, NLRP12, NLRC4, and NAIP
have been reported to operate via inflammasomes (Figure 2).
Other NLRs such as NOD1, NOD2, NLRP10, NLRX1, NLRC5,
and CIITA do not directly engage the inflammatory caspases,
but instead activate nuclear factor-κB (NF-κB), mitogen-activated
protein kinases (MAPKs), and interferon (IFN) regulatory fac-
tors (IRFs) to stimulate innate immunity. Below, we discuss the
different NLRs along with their mechanisms of activation and
diseases associated with defects in their activities (Figure 3).
www.frontiersin.org October 2013 | Volume 4 | Article 333 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Zhong et al. NLRs and disease
INFLAMMASOME-FORMING NLRs
In 2001, the causative mutation of Muckle–Wells Syndrome
(MWS), a rare autosomal recessive auto-inflammatory disease,
was mapped to NLRP3 (CIAS1) (17). In 2002, Tschopp and col-
leagues were the first to characterize the inflammasome, defining
it biochemically as a complex consisting of an NLR (NLRP1),
the bipartite adaptor protein ASC (which contains both a CARD
and a PYD), and the two inflammatory caspases, caspases-1
and -5 (18). In 2004, the discovery of the links between the
NLRP3 mutations, NLRP3 inflammasome hyper-activation, and
excessive production of IL-1β has set the stage for the use
of IL-1 blockade strategies, such as recombinant IL-1 receptor
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FIGURE 1 |The human NLR gene family. The human NLR gene family
consists of 22 members that share a tripartite structure, consisting of an
N-terminal signaling domain, a central nucleotide-binding and
oligomerization domain, and a C-terminal agonist sensing/ligand-binding
domain. The NLR family is sub-divided into four sub-groups NLRA, NLRB,
NLRC, and NLRP based on the nature of the N-terminal domain consisting
respectively of an acidic transactivation domain, a baculovirus IAP repeat
(BIR), a caspase-recruitment and activation domain (CARD), and a Pyrin
domain (PYD).
antagonist (anakinra) or anti-IL-1β antibodies (canakinumab),
to cure patients inflicted with hereditary periodic fever syn-
dromes [reviewed in Ref. (19)]. Concurrently, Dixit and colleagues
reported the generation of the first inflammasome knockouts,
namely mice deficient in IPAF (NLRC4) or the adaptor ASC,
and showed that macrophages from these mice had a defect
in IL-1β production following infection with flagellated bacte-
ria (20). As more inflammasome-forming NLRs are continuously
being characterized and studied, their importance in activating
immune responses and consequently in conferring host resistance
is becoming evident.
NLRP1
The NLRP1 protein has a unique structure amongst other NLRs.
Human NLRP1 contains a PYD on the N-terminus and a CARD on
the C-terminus, with ZU5 and UPA domains in the internal region
which confers proteolytic activity upon the protein (21). Three
murine NLRP1 homologs – Nlrp1a, Nlrp1b, and Nlrp1c – have
been identified, although they lack the N-terminal PYD domain
present in human NLRP1. Few ligands have been found for NLRP1
to date, and include bacterial products such as lethal toxin (LT)
produced by Bacillus anthracis which activates murine NLRP1b
(22), muramyl dipeptide (MDP), a component of bacterial pep-
tidoglycan that activates human NLRP1; and reduced levels of
cytosolic ATP (23–27).
Defects in NLRP1 have been linked to a variety of autoim-
mune disorders. Candidate gene analysis and Genome-wide asso-
ciation studies (GWAS) have shown a significant association of
polymorphic variants in the extended promoter and/or coding
regions of NLRP1 with familial cases of generalized vitiligo (28,
29), celiac disease (30), Addison’s disease and type 1 diabetes
(31, 32), autoimmune thyroid disorders (AITDs) (33), systemic
lupus erythematosus (SLE) (34), systemic sclerosis and giant
cell arteritis (35, 36), congenital toxoplasmosis (37), rheumatoid
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FIGURE 2 |The NLR inflammasomes. The three biochemically characterized
inflammasomes are depicted. The NLRP1 inflammasome consists of NLRP1,
ASC, and caspases-1 and -5. Little is known about the agonists that activate
NLRP1. Anthrax lethal toxin, MDP, and decreased cytosolic ATP have been
reported to stimulate this inflammasome. NAIP and NLRC4 form a caspase-1
inflammasome in response to bacterial flagellin and T3SS rod proteins.
NLRP3, on the other hand, is activated by a wide range of agonists including a
number of MAMPs and DAMPs.
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arthritis (38), and Alzheimer’s disease (39) (Figure 3). A novel
missense mutation M77T in NLRP1, which destabilizes the pro-
tein, has been recently shown to cause corneal intraepithelial
dyskeratosis (40).
In a recent analysis of high-risk haplotypes with substitutions
in human NLRP1, Levandowski et al. demonstrated that periph-
eral blood monocytes from heterozygous carriers of the haplo-
type 2A (which contains three non-synonymous substitutions:
L155H-V1059M-M1184V) process significantly greater amounts
of pro-IL-1β into mature IL-1β under basal conditions. It was
thus proposed that the enhanced production of IL-1β predis-
poses carriers to a wide spectrum of autoimmune diseases (41).
Consistently, patients diagnosed with vitiligo commonly suffer
from other autoimmune disorders such as SLE (28, 42). However,
the molecular mechanisms underlying the link between NLRP1
genetic variations and these disorders are still unknown. It is
plausible that deregulation of an NLRP1 inflammasome effec-
tor function is at the basis of the autoimmunity phenotypes.
This is consistent with recent results from mice. Masters et al.
have recently reported that mice with an activating mutation
in Nlrp1a exhibited increased T-cell progenitor death (pyrop-
tosis) at the steady state, which rendered them cytopenic (43).
In contrast, Nlrp1a-deficient mice, which may experience less
pyroptosis, develop an over-exuberant immune response (43).
However, while Masters et al. demonstrated that the inflamma-
tory disease in Nlrp1a mutant mice was dependent on caspase-
1, additional proof is needed to show that Nlrp1a formed an
inflammasome complex in vivo (43). While anakinra has been
shown to be successful in treating patients with SLE in prelimi-
nary studies, IL-1 blockade strategies have not been tested to date
for other autoimmune diseases such as vitiligo or celiac disease
(42, 44).
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FIGURE 3 | Continued
www.frontiersin.org October 2013 | Volume 4 | Article 333 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Zhong et al. NLRs and disease
NLRX1
NACHT LRR CARD AD BIR PYD ???
NLRX Susceptibility to chronic heptitis B 
infection
NLRP1
NLRP3
NLRP6
NLRP7
NLRP10
NLRP12
NLRP Generalized vitiligo
Addison’s disease, Type 1 diabetes
Celiac disease
Autoimmune thyroid disorders
Systemic lupus erythematosus
Systemic sclerosis
Giant cell arteritis
Congenital toxoplasmosis
Alzheimer’s disease
Corneal intraepithelial dyskeratosis
Rheumatoid arthritis
Predisposition to autoimmune diseases
Type 1 diabetes, Celiac disease
Psoriasis
Increased susceptibility to HIV-1 
Cryopyrin-associated periodic 
syndromes (CAPS)
Gout
Alzheimer’s disease
High fat diet induced obesity
Type 2 diabetes
Atherosclerosis
Multiple metabolic syndrome
-associated abnormalities
Colitis and colon cancer
Hydatidiform moles
Abnormal human pregnancies and
embryonic development
Reproductive wastage
Testicular and endometrial cancer
Susceptibility to bacterial infections
Atopic dermatitis
Hereditary periodic fever syndromes
rs1008588, rs2670600
rs12150220
rs12150220, rs2670660
rs2670660
rs8182352
rs8081261, rs11652907
rs2137722, rs34733791
rs11657747, rs11651595
M77T
rs878329
L155H-V1059M-M1184V
rs10754558, rs358294199
rs10733113G
rs10754558
R693W, R693D, N913S
Arg284X, 2072+3insT
Arg284X
Knock-in mouse models with NLRP3
mutations exhibited increase in IL-1β
Nlrp3-’- mice more susceptible to colitis
Nlrp3-’- mice protected from memory 
loss
Nlrp3-’- mice on high-fat diet have 
improved glucose tolerance 
mice protected from 
atherosclerosis in one study
Nlrp6-’- mice are more susceptible to colitis 
tumor development after carcinogen 
healing; gut microbiota dysbiosis;
resistance to some pathogens
NLRP10 knock-in mice resistant to 
LPS-induced endotoxic shock 
Nlrp10-’- mice has major defects in 
T cell responses after stimulation
Dermatitis
susceptible to bacterial challenge, 
colitis and colon cancer
More than 30 mutations in 
exon 3, e.g.
R260W, A352V, L353P
FIGURE 3 | NOD-like receptors and disease. NLRs have been
implicated in a plethora of diseases. Genetic studies have uncovered a
number of variants in genes encoding NLRs or their signaling mediators
associated with human diseases. Animal models have served as a key
discovery platform to characterize the underlying functions and
molecular mechanisms of NLRs in these diseases and associated
pathologies. Together, these efforts have led to therapeutic success in
the clinic for a subset of NLR-dependent auto-inflammatory diseases.
When available, the mutations and SNPs linked to disease are listed and
animal phenotypes are presented.
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NLRP3
The NLRP3 inflammasome is arguably the most studied inflam-
masome to date. NLRP3 is predominantly expressed in splenic
neutrophils, macrophages, monocytes, and conventional dendritic
cells, and its expression is inducible in response to inflamma-
tory stimuli (45). There is evidence suggesting that a two-step
process is required for NLRP3 activation. The first, or priming
signal, converges on the activation of NF-κB and transcriptional
induction of inflammasome components including NLRP3 itself
and pro-IL-1β. The second, or activating signal, in the form of a
microbial or danger signal, is then able to directly activate inflam-
masome assembly (46). NLRP3 is able to recognize a wide variety
of exogenous and endogenous stimuli such as microbial agonists,
ATP, and particulate matters (47, 48). There is, however, scarce
evidence that NLRP3 binds directly to its activators. Instead its
activation is thought to be triggered by signaling intermediates
(46). For instance, Shenoy et al. proposed that guanylate binding
protein 5 (GBP5) may play a vital role in activating inflammasome
assembly and promoting caspase-1 processing in response to live
bacteria and bacterial cell wall components (49). A recent study
by Zhong et al. suggested that particulate stimuli might induce
mitochondrial production of reactive oxygen species (ROS), which
triggers a calcium influx mediated by transient receptor poten-
tial melastatin 2 (TRPM2) to activate NLRP3 (50). The role of
ROS in NLRP3 activation is consistent with earlier results by
Zhou et al. who showed that ROS also leads to the dissociation of
thioredoxin-interacting protein (TXNIP) from thioredoxin, free-
ing it to interact with and activate NLRP3 (51). In addition, it
has been reported that NLRP3 activators are able to disrupt the
mitochondria, resulting in the release of oxidized mitochondrial
DNA and/or cardiolipin, which can bind to and activate NLRP3
(52, 53). Alternatively, it was argued that mitochondrial disruption
is not required for NLRP3 activation; instead K+ efflux is suffi-
cient to stimulate this NLR (54). NLRP3 inflammasome activation
may involve at least two adaptors, ASC and the mitochondria-
associated adaptor MAVS. It was recently shown that MAVS
recruits NLRP3 to the mitochondria for activation in response to
non-crystalline activators (55) and that microtubule-driven traf-
ficking of the mitochondria is necessary for NLRP3-ASC complex
assembly and activation (56).
Gain-of-function mutations in the NLRP3 gene were first
associated with cryopyrin-associated periodic fever syndromes
(CAPS), which are a group of rare hereditary auto-inflammatory
diseases including familial cold urticaria, MWS, and neonatal
onset multisystem inflammatory disease [reviewed in Ref. (19)].
Mutations in NLRP3 were reported to induce an overproduc-
tion of IL-1β that triggers the subsequent development of severe
inflammation (57, 58). A knock-in mouse model of MWS have
validated the observations made in human patients, and showed
that equivalent mutations in murine Nlrp3 lead to the produc-
tion of massive amounts of IL-1β, which mediates the disease (59,
60). IL-1 blockade therapies are frequently used to treat auto-
inflammatory diseases. Anakinra and canakinumab, for example,
have been used to treat CAPS patients with great success, as sev-
eral groups have reported long-lasting clinical responses as well as
the restoration of IL-1β production levels to normal amounts in
patients after treatment (61, 62).
NLRP3 was also linked to gout, which is a result of uric acid
crystal deposition in the joints as a consequence of a rich diet high
in purines (63). The exact mechanism of NLRP3 activation by uric
acid crystals is still unknown, but monosodium urate and calcium
pyrophosphate dihydrate crystals were found to induce NLRP3
and caspase-1 activation and the subsequent processing of IL-1β
and IL-18 (64). Since uric acid can also be released from dying
cells as a DAMP (65), there has been speculation that NLRP3 may
also detect danger signals released from dying cells (66).
Single nucleotide polymorphisms in the NLRP3 locus have
been associated with a wide range of disorders, including type 1
diabetes (67), celiac disease (67), psoriasis (68), and increased sus-
ceptibility to HIV-1 infections (69). While no SNP in the NLRP3
region is directly associated with inflammatory bowel disease
(IBD), a SNP downstream of NLRP3 has been previously iden-
tified as a risk allele in Crohn’s disease (70). Lewis and colleagues,
however, were unable to reproduce this result, as they found no
significant association between NLRP3 SNPs and Crohn’s disease
(71). A recent GWAS meta-analysis has shown that SNPs that
affect receptors downstream of NLRP3 such as IL18R1, IL1R1,
IL1RL1, IL1RL2, and IL1R2, are associated with susceptibility to
IBD (72). Thus, although there is conflicting data regarding the
effects of NLRP3 variants in IBD, defects in inflammasome signal-
ing likely play a role in IBD pathogenesis. Consistently, Nlrp3−/−
mice or mice deficient in inflammasome components were found
to be significantly more susceptible to experimental models of col-
itis compared to wild-type mice (73–76). Together, these studies
indicate that NLRP3 may be involved in intestinal tissue repair
mechanisms following injury.
The NLRP3 inflammasome has also been implicated in differ-
ent metabolic pathologies. For instance, the NLRP3 inflamma-
some has been linked to obesity, insulin resistance, atherosclerosis,
and Alzheimer’s disease. It has been shown that activation of
caspase-1 and IL-1β processing downstream of NLRP3 lead to
inhibition of adipocyte differentiation and contributes to high fat
diet-induced obesity (77). Several studies have also shown that the
NLRP3 inflammasome may play a crucial role in insulin resistance
and the potential development of type 2 diabetes (51, 77, 78). Con-
sistently, Nlrp3−/− or Asc−/−mice were reported to have improved
glucose tolerance and insulin sensitivity when fed a high fat diet.
Ceramide, a specific product from the metabolism of long-chain
saturated fatty acids, and the saturated free fatty acid, palmitate,
have been shown to induce IL-1β in an NLRP3-dependent fashion
[Ref. (78) and reviewed in Ref. (63)]. IL-1β produced downstream
of the NLRP3 inflammasome, which is also stimulated by islet
amyloid polypeptide (79), promotes beta-cell dysfunction, and
cell death (80), linking NLRP3 activation to insulin resistance.
Crystalline cholesterol was proposed to cause atherosclerosis by
acting as a danger signal and initiating inflammation through the
NLRP3 inflammasome. Consistently, Duewell et al. observed that
mice deficient in components of the NLRP3 inflammasome did
not undergo acute inflammation after the injection of cholesterol
crystals, and had markedly decreased atherosclerosis compared to
wild-type animals (81). There is, however, some controversy in
this area, as Menu et al. reported no differences in disease progres-
sion in Nlrp3−/− mice compared to wild-type animals (82). In
Alzheimer’s disease, amyloid-β aggregates were shown to activate
www.frontiersin.org October 2013 | Volume 4 | Article 333 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Zhong et al. NLRs and disease
NLRP3 ex vivo in primary macrophages and microglia (83). This
was supported by in vivo results by Heneka et al. who demonstrated
that NLRP3 deficiency protected mice with familial Alzheimer’s
disease mutations from memory loss (84).
NLRP6
Preliminary immunofluorescence data has proposed that the for-
mation of the NLRP6 inflammasome is dependent on the recruit-
ment of NLRP6 to ASC specks in the cytosol via its N-terminal
PYD (85, 86). While much of its functions still remain unknown,
recent studies have demonstrated that NLRP6 is important in the
self-renewal and integrity of the intestinal epithelium, as Nlrp6−/−
mice exhibited insufficient wound healing after injury (87, 88)
and were more susceptible to carcinogen-induced tumor develop-
ment compared with wild-type mice (89, 90). While the precise
mechanisms by which NLRP6 protects against tumorigenesis is
not clear. It is known that Nlrp6−/− mice are able to sustain
increases in intestinal epithelial proliferative activity over longer
periods of time along with the observed lower efficiency in wound
repair – in other words, the repair mechanism in Nlrp6−/− mice
fails to promote wound healing but is still able to promote gen-
eral cell proliferation, leading to higher incidents of dysplasia and
tumorigenesis (91).
In a study by Elinav et al., Nlrp6−/− mice showed an altered
gut microbiota with an increase in colitogenic bacterial strains
such as Prevotellaceae and TM7, which are also found in increased
numbers in IBD patients, indicating a role for NLRP6 in the
regulatory sensing system in the gut as well (92). The authors spec-
ulated that NLRP6 may act as a “gate keeper” by sensing bacterial
products or cell damage and promoting the production of IL-18
during homeostasis which in turn supports the normal micro-
bial flora in the gut to prevent dysbiosis (92). While this proposal
raised some interesting points as to the functions of NLRP6 in
the gut, a conclusion cannot be drawn as to whether the altered
microbiota in Nlrp6−/− animals is due to the absence of the
protein, as no littermate analysis or maternal microbiota trans-
fer experiments were conducted by the authors to further their
hypothesis. A study by Henao-Mejia et al. later linked changes in
Nlrp6−/− mice microbiota to metabolic diseases (93). Namely,
NLRP6 seems to negatively regulate the progression from non-
alcoholic fatty liver disease to non-alcoholic steatohepatitis by
preventing the increase in colitogenic bacteria (93). Additionally,
Anand et al. observed that Nlrp6−/− mice were highly resistant
to a variety of pathogens including Listeria monocytogenes and
Escherichia coli (94). Nlrp6−/− mice had increased numbers of
immune cells in their circulation, as well as enhanced activation of
MAPK and NF-κB signaling, though Toll-like receptor (TLR) acti-
vation, suggesting that NLRP6 may suppress TLR pathways after
the recognition of pathogens to prevent amplified inflammatory
pathology (94). The exact mechanisms of how NLRP6 functions,
however, still remain to be studied.
NLRP7
NLRP7, a human NLR with no murine orthologs, is character-
ized by an N-terminal PYD along with a NACHT domain and a
C-terminal LRR region. Mutations in the NLRP7 gene are associ-
ated with recurrent hydatidiform moles and reproductive wastage
(substitutions R693W, R693P, and N913S) (11, 95–97). Further-
more, NLRP7 expression is increased in certain type of cancers
such as testicular (98) and endometrial (99) cancers. However, the
mechanisms underlying these phenotypes are not clear. Messaed
et al. showed that PBMCs from patients with NLRP7 mutations
(at G118X, G380R, C399Y, R693W, A719V) secreted significantly
lower levels of IL-1β and TNF in response to LPS despite high
intracellular levels of pro-IL-1β and unimpaired pro-IL-1β pro-
cessing. The authors concluded that NLRP7 might play a role in
cytokine trafficking and secretion from the cell (100). Conversely,
others have shown that overexpression of NLRP7 inhibited pro-
IL-1β synthesis and secretion (88, 101). Moreover, it was recently
reported that bacterial acylated lipopeptides (acLP) activated
NLRP7 and stimulated formation of an NLRP7-ASC-caspase-1
inflammasome (102). Thus, further studies are needed to clarify
NLRP7 mechanisms of actions and functions in reproduction and
immunity.
NLRP12
NLRP12 was previously reported to form an inflammasome as well
as function in modulating NF-κB signaling (see below). A recent
study by Vladimer et al. has shown that the NLRP12 inflamma-
some has a key role in controlling IL-1β and IL-18 production
after Yersinia pestis infection, where NLRP12-deficient mice were
more susceptible to infection compared to the controls (103).
Other pathogens such as Klebsiella pneumoniae and Mycobac-
terium tuberculosis and bacterial components such as LPS do not
seem to depend on NLRP12 for infection or pathology (104).
While many of the functions and activators of NLRP12 remain
unknown, mutations in the NLRP12 gene have been associated
with auto-inflammatory diseases such as atopic dermatitis (105)
and hereditary periodic fever syndromes (106, 107). Anti-IL-1
therapies, similar to those administered to patients with NLRP3
mutations, have been conducted on patients with NLRP12 muta-
tions with limited success. Patients treated with anakinra showed
improvements early on during the treatment process, but devel-
oped resistance to the drug within months and suffered from
severe myalgia as a side effect (107). Similarly, levels of IL-1β in
these patients returned to pre-treatment levels after 14 months of
treatment (107). Further clinical studies are needed before con-
clusions are drawn regarding the efficacy of anti-IL-1 agents in the
treatment of diseases associated with NLRP12.
There is currently much debate as to the role of NLRP12 in
inflammation, and both stimulatory and inhibitory functions have
been proposed. Some studies have suggested that NLRP12 may
negatively regulate the NF-κB pathway (86, 108, 109). Nlrp12−/−
mice were found to be more susceptible to colitis and colon cancer,
and polyps isolated from these mice showed significantly higher
non-canonical activation of NF-κB with an increased expression
of inflammation and cancer-related genes (109, 110). Conversely,
Arthur et al. demonstrated in a murine model of allergic dermati-
tis that proinflammatory cytokine production was unaffected in
Nlrp12−/− mice (111). Instead, dendritic cells in Nlrp12−/− mice
exhibited a much-reduced migratory capacity, and neither periph-
eral dendritic cells nor neutrophils in Nlrp12−/− mice responded
to chemotaxic signals or chemokines in in vitro experiments (111).
Yet another function for NLRP12 was proposed by Jéru et al.,
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who discovered that mutations in NLRP12 did not affect NF-
κB activation, but rather increased ASC speck formation and
caspase-1 activation (112). Altogether, these results suggest that
NLRP12 plays a role in suppressing NF-κB while stimulating the
inflammasome and assisting in the migration of immune cells.
NLRC4 AND NAIPs
NLRC4 possesses an N-terminal CARD that allows direct inter-
action with caspase-1 independently of ASC (113, 114). A recent
study by Qu et al., showed that the phosphorylation of Ser533
in NLRC4 by PCKδ was crucial for the activation of the NLRC4
inflammasome (115). NAIPs, members of the NLRB sub-family,
have been identified as critical components of the NLRC4
inflammasome. They are required for the recognition of bacte-
rial components, as well as the scaffolding of the NAIP-NLRC4
inflammasome. Activators of this inflammasome include bacterial
flagellin and components of the bacterial type III secretion system
(T3SS) (113, 116, 117). Notably, murine Naip5 and Naip6 were
shown to recognize bacterial flagellin and subsequently bind to
NLRC4 to trigger the formation of the inflammasome, whereas
Naip2 and human NAIP serve as receptors for the rod and the
needle components, of the bacterial T3SS (118, 119).
NLRC4 plays an essential role in host survival and pathogen
clearance following host infection with pathogens such as
Legionella pneumophila (120, 121), Candida albicans (122), and
Burkholderia pseudomallei (123). More recently, Cai et al. showed
that, upon K. pneumoniae infections, Nlrc4−/− mice exhibited
decreased survival compared to wild-type animals (124). Similarly,
Franchi et al. reported that Nlrc4−/− mice were highly susceptible
to orogastric Salmonella infections (125). Interestingly, Nlrc4−/−
mice do not develop spontaneous colitis in response to the com-
mensal microbiota (126), likely due to low soluble flagellin levels in
the gut and a primary role of TLR5 in dealing with gut flagellated
bacteria. NLRC4 thus serves as an additional sentinel against path-
ogenic enteric infections (126, 127). NLRC4 has been previously
been shown to act in sync with NLRP3 during Salmonella infec-
tion (114). More recently, it was demonstrated that both NLRs play
non-redundant roles in B. pseudomallei infection and melioidosis,
where NLRC4 is critical for pyroptosis and NLRP3 for the produc-
tion of IL-1β and IL-18 (123). Ceballos-Olvera et al. demonstrated
that while IL-18 and pyroptosis are both essential for host resis-
tance, the production of IL-1β by NLRP3 was deleterious, as it
triggered excessive neutrophil recruitment and exacerbated the
disease (123). Thus NLRC4 seems to act synergistically with both
TLR5 and NLRP3, but its contributions to their functions seems
to be secondary.
NON-INFLAMMASOME-FORMING NLRs
NOD1/2
NOD1 and 2, have been studied primarily in the context of
their signaling activity following recognition of the peptidoglycan
components diaminopimelic acid (DAP) and MDP from Gram-
negative and Gram-positive bacteria (128–132). Despite this focus,
much of the nature of the NOD1 and 2 interaction with these
structures remains unknown, although recent findings suggest
that NOD2 directly binds MDP with high affinity (133), with
the N-glycosylated form specific to the mycobacterial cell wall
triggering an exceptionally strong immunogenic response com-
pared to N-acetyl MDP (134). The possibility of a role for NOD2
in non-bacterial infections has also been suggested, with NOD2
having been shown to induce an IFNβ-driven antiviral response
following recognition of single-stranded viral RNA (135). Indeed,
viral ssRNA from respiratory syncytial virus (RSV), vesicular
stomatitis virus (VSV), and influenza virus has been shown to
trigger a non-canonical NOD2-directed signaling pathway that
requires mitochondrial antiviral signaling protein (MAVS) and
induces IRF3 activity, leading to the production of type I IFNs
(135) (Figure 4). However, it is still unclear whether lack of NOD2
results in susceptibility to viral infection in humans.
NOD1 and 2 are encoded by the CARD4 and CARD15 genes
respectively, and as NLRCs, both contain the shared NOD and
LRR domains in addition to an amino-terminal CARD. Despite
the strong similarities between the two receptors, differences exist;
NOD1 contains one CARD domain, while NOD2 contains two
(136) and expression of NOD1 is detected in a wide variety
of cell types, whereas NOD2 expression is restricted to myeloid
cells (136–138), keratinocytes (139) and intestinal, lung, and oral
epithelial cells (140–142).
Activation of NOD1 and 2 follows the cytosolic recognition
of peptidoglycan ligands that triggers oligomerization of the
receptors via their NOD domain and the recruitment of mediators
needed to form a signaling complex referred to as the nodosome
(143). The nodosome is directed to the point of bacterial entry on
the plasma membrane of polarized epithelial cells by the regulatory
protein FRMBP2 (144). NOD1 and 2 both interact with RIPK2,
via a CARD–CARD homotypic interaction (145–148). This asso-
ciation results in the recruitment of a number of E3 ubiquitin
ligases, including TNF receptor-associated factors (TRAFs) (149),
cellular inhibitor of apoptosis (cIAP)1 and cIAP2 (150), X-linked
inhibitor of apoptosis (XIAP) (151, 152), and ITCH (153). K63-
linked ubiquitination of RIPK2 has been established as a means to
construct protein scaffolds that transduce downstream signaling.
In a step-wise fashion, ubiquitination of RIPK2 leads to activa-
tion and recruitment of the TAK1 complex, consisting of TAK1 in
association with TAK1-binding protein (TAB)2 and 3. The kinase
activity of TAK1 leads to phosphorylation events that activate AP-1
and NF-κB. In parallel to cIAP-induced ubiquitination of RIPK2,
XIAP’s enzymatic activity results in the formation of polyubiqui-
tin chains on RIPK2, serving as a platform to engage another E3
ligase complex known as the Linear Ubiquitin Assembly Complex
(LUBAC) (152, 154). LUBAC attaches linear ubiquitin chains to
the regulatory protein NEMO, allowing for activation of the IKK
complex. The kinase activity of IKKβ results in the phosphoryla-
tion and degradation of the inhibitor of NF-κB (IκB), allowing for
NF-κB dimers to translocate to the nucleus and induce proinflam-
matory gene expression (155). Besides activating NF-κB, NOD1
and NOD2 have also been shown to activate the p38, JNK, and
ERK MAPK pathways (147, 156, 157) and to interact with other
NLRs such NLRP1 and NLRP12 (158, 159) (Figure 4).
NOD1 and 2 have been implicated in a number of chronic
inflammatory diseases. Mutations and SNPs in CARD15 in par-
ticular, have been linked to a multitude of inflammatory diseases
including Crohn’s disease (160,161),Blau Syndrome (162),asthma
(163, 164), atopic eczema (165), atopic dermatitis (105), arthritis
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FIGURE 4 | NOD1/2 signaling pathways. The NOD1 and 2 receptors
recognize the bacterial peptidoglycan derivatives DAP and MDP. The events
involved in signal transduction are depicted and involve the formation of a
nodosome complex that is stabilized through a series of ubiquitin scaffolds
mediated by a number of E3 ligases including cIAP1/2, XIAP, LUBAC, and
ITCH. These scaffolds serve to engage effector kinases, including TAK1 and
the IKK complex to activate NF-κB and MAPK pathways. NOD2 is additionally
activated by single-stranded RNA viruses and stimulates an antiviral innate
immune response by engaging MAVS and activating IRF3. The NOD receptors
have also been shown to synergize with NLRP sensors to activate the
inflammasome. Conversely, they have also been implicated in triggering
autophagy though association with ATG16L1, and in response to viral
infection, to inhibit the inflammasome by upregulating ULK1-dependent
mitophagy.
(166, 167), and sarcoidosis (168). In the context of Crohn’s dis-
ease, the most common mutation that confers susceptibility is
a frameshift mutation in the LRR region of the receptor (160),
while the mutations conferring susceptibility to Blau syndrome
occur in the NOD region (162). While the contribution of these
mutations to disease is unknown, further work on understand-
ing NOD2 function could unveil the link between the gene and
the disease, as well as allow for the creation of new therapies for
these chronic and often devastating diseases. Several NOD2 loss-
of-function mouse lines have been generated in an attempt to
elucidate its role in Crohn’s disease. Pauleau and Murray gener-
ated the first NOD2 knockout mice (156). Surprisingly, these mice
lacked symptoms associated with spontaneous intestinal inflam-
mation, although stimulation of primary macrophages from these
animals with MDP failed to trigger inflammatory responses, con-
firming loss of NOD2 activity (156). Other NOD2 mouse mutants
were later generated to express common Crohn’s disease suscepti-
bility mutations (157, 169). While these mice did not develop any
gut inflammation resembling that of Crohn’s disease patients, they
did display increased susceptibility to bacterial infection, and were
shown to produce decreased amounts of β-defensins when chal-
lenged with L. monocytogenes (157, 170). Similarly, mice deficient
in NOD1, NOD2, or RIPK2 also exhibited enhanced susceptibil-
ity to bacteria including Helicobacter pylori (171–173), Chlamy-
dophila pneumoniae (174), L. pneumophila (172, 175, 176), and B.
anthracis (177). This susceptibility often resulted from an inabil-
ity to control bacterial burden, possibly due to a reduced ability to
recruit neutrophils as well as a decrease in the production of proin-
flammatory and antimicrobial molecules (176, 177). Despite the
prevalence of NOD2-deficient models, there remains controversy
as to whether Crohn’s disease-linked mutations in NOD2 dimin-
ish or enhance its activity in the context of the disease. Common
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Crohn’s disease-associated NOD2 variants expressed in HEK293T
kidney cells are unable to detect MDP and activate NF-κB (178)
and monocytes from Crohn’s disease patients with the 1007fs vari-
ant displayed defects in the secretion of TNFα, IL-6, IL-8, and IL-10
(179, 180) and many of these NOD2 variants seem to act reces-
sively (181). While these findings point to a loss-of-function effect
of the mutations, Karin and colleagues have argued that the mod-
els used in these studies lack resemblance to the natural course
of the disease in humans and that the Crohn’s disease-associated
NOD2 mutations may in fact result in a gain-of-function. Indeed,
Crohn’s disease has been associated with the presence of activated
NF-κB and inflammatory NF-κB target gene products in epithe-
lial cells and lamina propria macrophages (182, 183) rather than
in circulating blood monocytes used in studies with cultured cells,
and results from experiments using tissue samples have differed
from those using monocytes (179).
The study of NOD2 linkage to Crohn’s disease has been
extended to encompass a key role of NOD1 and 2 in the regula-
tion of autophagy. Autophagy is a housekeeping process in which
organelles or other cellular components are degraded and recycled
into nutrients during times of starvation or stress. This process
results in the formation of a double membrane vacuole known
as the autophagosome, which fuses with lysosomes to degrade its
contents (184). The role of NOD1 and 2 in this process was initially
proposed following GWAS findings of an association between a
key component of the autophagy process, ATG16L1, and suscep-
tibility to Crohn’s disease (185, 186). Not only have NOD1 and 2
been shown to interact with ATG16L1 (187), but murine Paneth
cells expressing the ATG16L1 mutation associated with Crohn’s
disease were unable to produce antimicrobial peptides despite
NOD2 stimulation (188). Additionally, the autophagic machinery
is involved in loading antigen onto MHC Class II, a process that has
been observed to be defective in Crohn’s disease (189). Recently,
Lupfer et al. further substantiated the link between NOD2 and
autophagy by demonstrating a role for NOD2-RIPK2 signaling
in the regulation of the NLRP3 inflammasome following infec-
tion with influenza A virus. By triggering the phosphorylation of
the autophagy inducer ULK1, RIPK2 induces autophagy of dis-
rupted mitochondria (mitophagy), preventing the accumulation
of ROS and NLRP3 inflammasome activation. Mice lacking Nod2,
Ripk2, or Ulk1 were hypersusceptible to influenza A infection due
to a hyperactive NLRP3 inflammasome and excessive IL-18 lev-
els (190) (Figure 4). Collectively, these studies provide evidence
for a key role of NOD2 in autophagy-associated processes such as
xenophagy, antigen presentation, antimicrobial peptide secretion,
and mitophagy.
Other diseases have also been associated with genetic variants
in loci encompassing the genes encoding NOD1 and/or 2. GWAS
have linked SNPs in CARD15 to prostate (191) and endometrial
(192) cancer, as well as to gastric lymphoma induced by H. pylori
infection (173). Similarly, SNPs in CARD15 were linked to sus-
ceptibility to leprosy (193, 194) and tuberculosis (195, 196). The
observation that CARD15, RIPK2, and NF-κB have been linked to
leprosy (193), tuberculosis (195, 197, 198), and IBD (150, 199) by
GWAS and other genetic studies in humans and mice, has led to
speculation of a common etiology between mycobacterial diseases
and Crohn’s disease (197, 200, 201).
NLRP10
NLRP10 was discovered based on its homology to NLRP3 and
APAF1 (202). Lack of LRRs in NLRP10 may indicate a role for this
protein as a signaling adaptor rather than an NLR sensor. NLRP10
has been found in human and murine skin (203), colon, kidney,
and testis (204), with mRNA and protein expressed in epithe-
lial cells (202, 205) and hematopoietic cells (206). NLRP10 was
previously proposed as a negative regulator of NF-κB, cell death,
and IL-1β release (202). These results have been supported by
NLRP10 over-expression studies in Nlrp10 knock-in mice and in
in vitro studies. In the murine model, Nlrp10 knock-in mice were
found to be resistant to LPS-induced endotoxic shock, due to a
decreased release of inflammatory cytokines (203). This was con-
sistent with the observation that cells from these animals secreted
reduced amounts of IL-1β following infection with Salmonella
or TLR7 stimulation (203). However, another group proposed a
role for NLRP10 in augmenting the NOD1 immune response to
Shigella flexneri, indicating the possibility of an inflammasome-
independent function for NLRP10 (205). While this mechanism
is still poorly understood, the ability of NLRP10 to interact with
NOD1 as well as its signaling targets RIPK2, TAK1, and NEMO,
suggests that NLRP10 may be involved in optimizing cytokine
release following bacterial infections. Furthermore,Flavell and col-
leagues reported a role of NLRP10 in adaptive immunity. Using
NLRP10 knockout mice, this group examined T-cell responses to
ovalbumin and aluminum hydroxide, complete Freund’s adjuvant
with myelin oligodendrocyte glycoprotein, and LPS. Interestingly,
Nlrp10−/− mice displayed major defects in TH2, TH17, and TH1
responses, potentially due to a defect in the ability of dendritic cells
to transport antigen to draining lymph nodes (207). These find-
ings, as well as those of another group that reported hematopoietic
compartment-dependent susceptibility of Nlrp10−/− mice to C.
albicans (206), highlight a role for NLRP10 in bridging innate and
adaptive immunity. Despite these findings, understanding the role
of NLRP10 in immunity is still in its infancy, and applications of
this protein to human diseases are limited while the function of
NLRP10 remains largely uncharacterized. However, GWAS have
linked NLRP10 to atopic dermatitis (105, 165, 208), an interesting
find considering the abundant expression of NLRP10 in the skin.
NLRX1
NLRX1 is unique among NLRs in that it contains an N-terminal
mitochondrial targeting sequence (209, 210). The protein is
broadly expressed in the mitochondria, although it is yet unclear
whether it is localized to the matrix or to the outer membrane
(209, 211). NLRX1 has been shown to enhance ROS production
when it is overexpressed (212), following Chlamydia (213) and
Shigella infection, as well as in response to TNFα and poly(I:C)
(212). Like NOD2, NLRX1 has been implicated in host antiviral
responses following viral RNA detection (135, 212) and has been
shown to directly bind both single and double stranded viral RNA
via its LRRs (210). Moore and colleagues initially characterized
NLRX1 as a negative regulator of MAVS and antiviral signaling
(211). Recently, Lei et al. demonstrated a role for NLRX1 and
the mitochondrial protein TUFM in enhancing autophagy and
reducing type I IFNs following viral infection (214, 215). How-
ever, these findings have been contested and the generation of
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NLRX1-deficient and Nlrx1 knockdown mice by several groups
has produced conflicting results. In some laboratories, the NLRX1
mutant mice did not display any differences in MAVS antiviral
signaling compared to wild-type controls (216–219). In contrast,
another group’s findings supported their original claim of a role
for NLRX1 in inhibiting MAVS signaling pathways (216, 218).
Zhao et al. recently associated a missense mutation in the LRR
of NLRX1 with susceptibility to chronic hepatitis B infection in
human patients. The replacement of the highly conserved Arg707
with a cysteine between a α helix and a β strand was hypothe-
sized to interfere with the electrostatic potential of the region and
consequently modulate the activity of the protein (220). Lastly, a
group characterizing the molecular signature of SIV-induced gas-
trointestinal dysfunction found an increase in NLRX1 expression
in rhesus macaques 90 days following SIV infection (221). These
findings highlight the role of NLRX1 in antiviral defense, but more
research is needed to elucidate the precise mechanism.
NLRC5
One of the newest additions to the NLR family, NLRC5 has been
shown to have a similar structure to other NLRs, although the
CARD domain has been found to be structurally distinct from
CARD domains expressed in other NLRs. The protein is most
similar to CIITA, both in structure and activity. NLRC5 has been
shown to be able to enter the nucleus, and its main function is
believed to be as a MHC Class I transactivator, forming the basis
of an enhanceosome for MHC Class I transcription (222). Accord-
ingly, NLRC5 is expressed constitutively in both humans and mice,
unlike the more restricted expression of CIITA (223, 224) and
knockdown of NLRC5 in cells using siRNA and in knockout mice
resulted in a decrease in MHC Class I expression, without sig-
nificantly affecting expression of MHC Class II (222, 225, 226).
Despite the widespread expression of NLRC5, however, there is
a distinct upregulation of NLRC5 in lymphocytes compared to
other hematopoietic and somatic cells (227, 228). As a key regu-
lator of MHC Class I transcription, NLRC5 expression has been
shown to be induced by a number of signals, including IFNβ,
poly(I:C), VSV, and LPS (222–225, 227, 228). However, the most
efficient activator of NLRC5 known is IFNγ, which several of the
aforementioned signals are known to induce. IFNγ functions via
signal transducer and activator of transcription 1 (STAT1) and
cannot induce NLRC5 expression in the absence of STAT1 (225,
228).
The effect of NLRC5 on human health and disease has yet to
be extensively studied. However, inferences can be made based
on NLRC5’s role in MHC Class I presentation and phenotypes
observed in NLRC5-deficient mice. Yao et al. observed extreme
immunodeficiency in these mice, with the animals unable to
mount an effective CD8+ T-cell response when challenged with
L. monocytogenes. Interestingly, NLRC5 deficiency also seemed to
result in a decrease in NLRP3 inflammasome activation, suggesting
that NLRC5 may play a role in the regulation of this pathway (226).
Murine and cellular models of NLRC5 deficiency have also impli-
cated NLRC5 in the negative regulation of TLR signaling (223, 229,
230), as well as in RIG-I-like receptor signaling(229). However,
other groups have disputed these findings (222, 230), and more
research needs to be done in order to gain a more comprehensive
understanding of the functions of NLRC5.
CLASS II TRANSACTIVATOR (CIITA)
MHC CIITA was discovered in 1993 as the genetic basis of heredi-
tary major histocompatibility complex Class II deficiency, or bare
lymphocyte syndrome (BLS), a disease characterized by severe
immunodeficiency due to a lack of MHC Class II expression (231).
Its detection via complementation cloning marked the discovery
of the first NLR family member, although the classification of
NLRs was only later introduced, following the discovery of NOD1.
Although CIITA retains the tripartite structure consistent across
the NLR family, it contains an additional acidic domain and a pro-
line/serine/threonine (PST)-rich domain at its N-terminus. Unlike
other NLRs, the function of CIITA lies in transcriptional regula-
tion of MHC Class II. The previously mentioned additions to the
structure of CIITA do not allow it to bind DNA, but provide a plat-
form for the recruitment and interaction of proteins required for
the transcription of MHC Class II in leukocytes or other cells fol-
lowing IFNγ stimulation (232–234). Accordingly, CIITA contains
nuclear localization signals and nuclear export signals (235–237).
As its role suggests, CIITA is expressed in cells that express MHC
Class II, mainly lymphocytes, dendritic cells, macrophages, and
other professional antigen presenting cells.
In addition to BLS, CIITA has been linked to a number of other
human diseases. GWAS and patient exome sequencing studies have
linked SNPs in CIITA to celiac disease (238, 239), susceptibility
to myocardial infarction (240), rheumatoid arthritis (240–242),
multiple sclerosis (240, 242), primary adrenal insufficiency (243),
SLE (244), and type 1 diabetes (245, 246), although these results
have not always been replicated in subsequent studies (247–249).
Gyllenberg et al. suggested that age-dependent variation in the
gene encoding CIITA could be responsible for false associations in
GWAS (250). Interestingly, women over 75 years of age express-
ing the rs3087456(G) allele were found to have a higher average
bone mineral density and a decrease in bone fractures compared
to controls, although the association was not observed in women
aged 25 years (251). Ulrich Streidl and colleagues recently used
RNA sequencing to identify a novel and frequently expressed
CIITA-BX648577 gene fusion product in the KM-H2 Hodgkin
lymphoma cell-line which was associated with decreased HLA
Class II expression and increased programed cell death 1 (PDL1)
on the surface of affected cells (252). Genomic CIITA breaks were
found to occur frequently in B-cell lymphoma patients; 38% of
primary mediastinal B-cell lymphoma patients and 15% of clas-
sical Hodgkin’s lymphoma patients displayed them. The group
also observed a decrease in survival in B-cell lymphoma patients
expressing genomic CIITA breaks compared to control. The role of
CIITA gene fusion products in B-cell lymphomas remains a field of
considerable interest. Understanding the effect of these genomic
breaks could lead to novel therapies for a highly treatment-evasive
cancer. At the very least, the discovery of these abnormal gene
products could lead to the discovery of new biomarkers, which
aid clinicians in stratifying patients according to prognosis and
predicted therapeutic response.
CONCLUSION
NOD-like receptors have been described as master regulators
of innate immunity, and research performed on the functions
and signaling pathways of these proteins continues to support
this claim. NLRs are essential in recognition of microbial- and
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pathogen-associated molecular patterns (MAMPs and PAMPs),
and have the ability to initiate and support robust immune
responses through the formation of inflammasomes and the acti-
vation of NF-κB, IRF, and MAPK pathways. Functions such as
the enhancement of MHC transcription and presentation impli-
cate NLRs in adaptive immunity, and their roles in reproduction,
indicate a broader responsibility of this gene family than pre-
viously suspected. The potency of NLRs in inducing immune
defenses is vital for the host, but can also provide serious prob-
lems when dysregulation or malfunction occurs. GWAS have
found many SNPs in NLR genes associated with a plethora of
inflammatory and autoimmune pathologies. Research is vastly
expanding contemporary knowledge on the functions and roles
of NLRs, but several NLRs still remain poorly characterized and
understood. Specifically, it remains unclear how NLRs can inter-
act with various and structurally diverse ligands. It is hypothesized
that upstream receptors or effectors dictate the activation of NLRs.
Alternatively, NLRs might employ co-receptors or dimerize with
additional sensors to achieve their functions. Further description
of the roles of NLRs in initiating and perpetuating human disease,
as well as the role of NLRs at the steady state,will prove vital to gain-
ing a comprehensive understanding of many human pathologies
and will provide novel targets and therapies for patients afflicted
with these diseases.
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